Research Discipline(s): Clinical, Health Services, Perioperative Care
Primary Title: Professor
Additional Titles & Affiliations:
RESEARCH TOPICS
Hormones, Ovarian Cancer, GTN, Endometrial Cancer
My goal is to improve care for patients in Manitoba living with gynecologic malignancies, and help Manitoba lead the way in oncology treatments.
Research Summary
Dr. Altman’s research interests include perioperative care, hormonal therapy, ovarian cancer and vulvar cancer. His pursuits are to continue providing quality evidence based treatment of cancer in Manitoba while building a research program to improve outcomes and survival.
Goals
I hope to continue increasing Manitoba’s participation in national and international trials. I would ideally like our center to continue being involved in further studies on chemotherapy resistant cancers. This will help to provide options for patients that have very few alternatives. I continue to do collaborative trials with other Canadian cities, using our combined resources more efficiently. We will continue to expand the MOCO and MOCR groups, with recent funding for further basic science research, we hope to begin working on translational details and clinical relevance. I will be working with the three international ERAS groups (gyne, HIPEC and vulvar/vaginal) to keep Manitoba at the forefront of enhanced recovery.
Research Biography
Since arriving in Manitoba I have continued to actively be involved in clinical research. In the past 11 years, I have published or been an author on over 70 peer reviewed articles. I have also enthusiastically presented at various meetings including the annual general meeting at the Society of Gynecologic Oncology of Canada (GOC), the Society of Obstetrics and Gynecology of Canada (SOGC), and the International Gynecologic Cancer Society meeting (IGCS).
Achievements
- Society of Obstetrics and Gynecology of Canada, Carl Nimrod award (2020)
- Atlee lecturer for Dalhousie’s 150th anniversary (November 2018)
- Professional Association of Residents and Interns of Manitoba (PARIM) Educator of the year nominee (2013/14)
- The Society of Gynecologic Oncology People’s choice poster presentation (2012)
-
Featured Publications
- Altman AD, Rozenholc A, Sacaragic L, Liu X. Nelson GS. The Canadian Gynecologic Oncology Peri-operative Management Survey: Re-examining the state of Enhanced Recovery After Surgery (ERAS) Recommendations; Int J Gynecol Cancer. 2022 Jun 24
- Poliquin V, Singh P, Leilike M, Al-Wazzan A, Dean E, Altman A.D. The risk of febrile morbidity following massive intraoperative blood loss during gynecologic laparotomy. J Obstet Gynaecol Can. 2021 Jan;43(1):19-25.
- Altman AD, Robert M, Armbrust R, Fawcett WJ , Nihira M, Jones CN, Tamussino K, Sehouli J, Dowdy SC, Nelson G. Guidelines for Vulvar and Vaginal Surgery: Enhanced Recovery After Surgery (ERAS®) Society Recommendations. American Journal of Obstetrics and Gynecology (2020), VOLUME 223, ISSUE 4, P475-485, OCTOBER 01, 2020 https://doi.org/10.1016/j.ajog.2020.07.039
- Cabasag CJ, Butler J, Arnold M, Rutherford M, Bardot A, Ferlay J, Morgan E, Møller B, Gavin A, Norell CH, Harrison S, Saint-Jacques N, Eden M, Rous B, Nordin A, Hanna L, Kwon J, Cohen PA, Altman AD, Shack L, Kozie S, Engholm G, De P, Sykes P, Porter G, Ferguson S, Walsh P, Trevithick R, O'Connell D, Bray F, Soerjomataram I. Exploring variations in ovarian cancer survival by age and stage (ICBP SurvMark-2): a population-based study. Gynecol Oncol. 2020 Jan 28. pii: S0090-8258(19)31877-3.
- V. Carlson, L. Walters, P. Lambert, E. Dean, R. Lotocki, A.D. Altman. Low-risk gestational trophoblastic neoplasia in Manitoba: experience with alternating Methotrexate and Actinomycin-D. Int J Gynecol Cancer. 2018 Aug 7
- A.D. Altman, J. McGee, T. May, K. Lane, L. Lu, W. Xu, P. Ghatage, B. Rosen. Neoadjuvant chemotherapy and chemotherapy cycle number: A national multicentre study. Gynecol Oncol. 2017 Aug 8. pii: S0090-8258(17)31228-3
- A.D. Altman, P Lambert, A.J. Love, D Turner, R Lotocki, E Dean, S Popowich, M.W. Nachtigal. Examining the effects of time-to-diagnosis, income, symptoms and incidental detection on overall survival in ovarian cancer: Manitoba Ovarian Cancer Outcomes (MOCO) study group. Int J Gynecol Cancer. 2017 Oct;27(8):1637-1644
- A.D. Altman, S.E. Ferguson, S. Lau, L.T. Gien, B. Gilks, B. Clarke, J.N. McAlpine, M. Kobel, A. Cameron, G. Nelson, G. Han, V. Samouelian, T.C. Ho, K. Louie, T. Panzarella, E.G. Atenafu, M.Q. Bernardini. Canadian High Risk Endometrial Cancer (CHREC) Consortium: Analyzing the Clinical Behaviour of High Risk Endometrial Cancers. Gynecol Oncol. 2015 Nov;139(2):268-274
